Integrative bioinformatics analysis reveals new prognostic biomarkers of clear cell renal cell carcinoma

Clinical Chemistry

Volumn 60, Issue 10, 2014, Pages 1314-1326

  Butz, Henriett ^a,b   Szabó, Peter M ^c   Nofech Mozes, Roy ^a   Rotondo, Fabio ^a   Kovacs, Kalman ^a   Mirham, Lorna ^a   Girgis, Hala ^a   Boles, Dina ^a   Patocs, Attila ^d   Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; GRAINYHEAD LIKE 2; KIAA0101 PROTEIN; MESSENGER RNA; MICRORNA; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CARRIER PROTEIN; DNA BINDING PROTEIN; GRHL2 PROTEIN, HUMAN; KIAA0101 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENE INTERACTION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MOLECULAR INTERACTION; PATHOGENESIS; PROTEIN EXPRESSION; UPREGULATION; BIOLOGY; CELL MOTION; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SEQUENCING; KIDNEY TUMOR; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DATA INTERPRETATION, STATISTICAL; DATABASES, GENETIC; DNA-BINDING PROTEINS; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; PROGNOSIS; RECEPTORS, ARYL HYDROCARBON; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84921820539     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.225854     Document Type: Article

References (41)

1. Cairns P. Renal cell carcinoma. Cancer Biomark 2010;9:461-73.
2. Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol [Epub ahead of print 2014 May 29].
3. Lopez JI. Renal tumors with clear cells. A review. Pathol Res Pract 2013;209:137-46.
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endes-felder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
5. Chen J, Zhang D, Zhang W, Tang Y, Yan W, Guo L, Shen B. Clear cell renal cell carcinoma associated microRNA expression signatures identified by an integrated bioinformatics analysis. J Transl Med 2013;11:169.
6. Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 2012;72:112-21.
7. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013;45:860-7.
8. Mohammed N, Rodriguez M, Garcia V, Garcia JM, Dominguez G, Pena C, et al. EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages. Oncol Lett 2011;2:719-24.
9. Chang CN, Feng MJ, Chen YL, Yuan RH, Jeng YM. p15(PAF) is an Rb/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression. PLoS One 2013;8:e61196.
10. Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, et al. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 2013;34:2231-9.
11. Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease. Cell 2011;144:986-98.
12. Jothi R, Balaji S, Wuster A, Grochow JA, Gsponer J, Przytycka TM, et al. Genomic analysis reveals a tight link between transcription factor dynamics and regulatory network architecture. Mol Syst Biol 2009;5:294.
13. Liu YY, Slotine JJ, Barabasi AL. Control centrality and hierarchical structure in complex networks. PLoS One 2012;7:e44459.
14. Henderson-Maclennan NK, Papp JC, Talbot CC Jr, McCabe ER, Presson AP. Pathway analysis software: annotation errors and solutions. Mol Genet Metab 2010;101:134-40.
15. Hockley SL, Mathijs K, Staal YC, Brewer D, Gid-dings I, van Delft JH, Phillips DH. Interlaboratory and interplatform comparison of microarray gene expression analysis of HepG2 cells exposed to benzo (a) pyrene. OMICS 2009;13:115-25.
16. Severgnini M, Bicciato S, Mangano E, Scarlatti F, Mezzelani A, Mattioli M, et al. Strategies for comparing gene expression profiles from different mi-croarray platforms: application to a case-control experiment. Anal Biochem 2006;353:43-56.
17. Yang OC, Maxwell PH, Pollard PJ. Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences. Kidney Int 2013; 84:667-81.
18. Huang TC, Chang HY, Chen CY, Wu PY, Lee H, Liao YF, et al. Silencing of miR-124 induces neu-roblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR. FEBS Lett 2011;585:3582-6.
19. Schlezinger JJ, Liu D, Farago M, Seldin DC, Bel-guise K, Sonenshein GE, Sherr DH. A role for the aryl hydrocarbon receptor in mammary gland tu-morigenesis. Biol Chem 2006;387:1175-87.
20. Gonzalez FJ, Fernandez-Salguero P. The aryl hydrocarbon receptor: studies using the AHR-null mice. Drug Metab Dispos 1998;26:1194-8.
21. Abel J, Haarmann-Stemmann T. An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol Chem 2010;391:1235-48.
22. Marlowe JL, Fan Y, Chang X, Peng L, Knudsen ES, Xia Y, Puga A. The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apopto-sis. Mol Biol Cell 2008;19:3263-71.
23. Ishida M, Mikami S, Kikuchi E, Kosaka T, Miyajima A, Nakagawa K, et al. Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 2010;31:287-95.
24. Callero MA, Suarez GV, Luzzani G, Itkin B, Nguyen B, Loaiza-Perez AI. Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. Int J Oncol 2012;41:125-34.
25. Maayah ZH, Ansari MA, El Gendy MA, Al-Arifi MN, Korashy HM. Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway. Arch Toxicol 2013;88:725-38.
26. Mikami S, Oya M, Mizuno R, Murai M, Mukai M, Okada Y. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogen-esis. Cancer Sci 2006;97:875-82.
27. Cieply B, Farris J, Denvir J, Ford HL, Frisch SM. Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Res 2013;73:6299-309.
28. Chen W, Xiao LZ, Oh JE, Shin KH, Kim RH, Jiang M, et al. Grainyhead-like 2 (GRHL2) inhibits keratino-cyte differentiation through epigenetic mechanism. Cell Death Dis 2012;3:e450.
29. Xiang X, Deng Z, Zhuang X, Ju S, Mu J, Jiang H, et al. Grhl2 determines the epithelial phenotype of breast cancers and promotes tumor progression. PLoS One 2012;7:e50781.
30. Emanuele MJ, Ciccia A, Elia AE, Elledge SJ. Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate. Proc Natl Acad Sci USA 2011;108:9845-50.
31. Jain M, Zhang L, Patterson EE, Kebebew E. KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PLoS One 2011;6:e26866.
32. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008;68:650-6.
33. Su X, Zhang T, Cheng P, Zhu Y, Li H, Li D, et al. KIAA0101 mRNA overexpression in peripheral blood mononuclear cells acts as predictive marker for hepatic cancer. Tumour Biol 2013;35:2681-6.
34. Papagiannakopoulos T, Kosik KS. MicroRNAs: regulators of oncogenesis and stemness. BMC Med 2008;6:15.
35. Zhao WH, Wu SQ, Zhang YD. Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L. Int J Mol Med 2013;32:101-7.
36. Lee MR, Kim JS, Kim KS. miR-124a is important for migratory cell fate transition during gastrulation of human embryonic stem cells. Stem Cells 2010;28: 1550-9.
37. Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, et al. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res 2013;73:990-9.
38. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S, et al. Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn 2010;12:687-96.
39. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012;7:e35661.
40. Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 2011;141:2076-87.
41. Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, et al. Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. Cell Biochem Funct 2013;31:319-24.